Abstract
Introduction
Decision-making in cancer-related venous thromboembolism (VTE) is often founded on scant lines of evidence and weak recommendations. The aim of this work is to evaluate the percentage of agreement surrounding a series of statements about complex, clinically relevant, and highly uncertain aspects to formulate explicit action guidelines.
Materials and methods
Opinions were based on a structured questionnaire with appropriate scores and were agreed upon using a Delphi method. Questions were selected based on a list of recommendations with low evidence from the Spanish Society of Oncology Clinical Guideline for Thrombosis. The questionnaire was completed in two iterations by a multidisciplinary panel of experts in thrombosis.
Results
Of the 123 statements analyzed, the panel concurred on 22 (17%) and another 81 (65%) were agreed on by qualified majority, including important aspects of long-term and prolonged anticoagulation, major bleeding and rethrombosis management, treatment in special situations, catheter-related thrombosis and thromboprophylaxis. Among them, the panelists agreed the incidental events should be equated to symptomatic ones, long-term and extended use of full-dose low-molecular weight heparin, and concluded that the Khorana score is not sensitive enough to uphold an effective thromboprophylaxis strategy.
Conclusion
Though the level of consensus varied depending on the scenario presented, overall, the iterative process achieved broad agreement as to the general treatment principles of cancer-associated VTE. Clinical validation of these statements in genuine practice conditions would be useful.
Similar content being viewed by others
References
Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122:1712–23.
Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484–8.
Font C, Carmona-Bayonas A, Fernández-Martinez A, Beato C, Vargas A, Gascon P, et al. Outpatient management of pulmonary embolism in cancer: data on a prospective cohort of 138 consecutive patients. J Natl Compr Canc Netw. 2014;12:365–73.
Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809–15.
Palumbo A, Palladino C. Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance. Ther Adv Drug Saf. 2012;3:255–66.
Siragusa S, Armani U, Carpenedo M, Falanga A, Fulfaro F, Imberti D, et al. Prevention of venous thromboembolism in patients with cancer: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res. 2012;129:e171–6.
Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141:7S–47S.
Farge D, Bounameaux H, Brenner B, Cajfinger F, Debourdeau P, Khorana AA, et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016;17:e452–66.
Muñoz Martín AJ, Font Puig C, Navarro Martín LM, Borrega García P, Martín Jiménez M. Clinical guide SEOM on venous thromboembolism in cancer patients. Clin Transl Oncol. 2014;16:1079–90.
Lyman GH, Bohlke K, Falanga A. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of clinical oncology clinical practice guideline update. J Oncol Pract. 2015;11:e442–4.
Watson HG, Keeling DM, Laffan M, Tait RC, Makris M. Guideline on aspects of cancer-related venous thrombosis. Br J Haematol. 2015;170:640–8.
Carrier M, Khorana AA, Zwicker JI, Noble S, Lee AYY. Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH. J Thromb Haemost. 2013;11:1760–5.
Olmos VP, Ramos Gallo MJ, Rebollo MA, Ortega DB, Docampo LI, Romera-Villegas A, et al. Management of venous thromboembolism in oncological patients: Spanish clinical practice guidelines. Consensus SEACV-SEOM. Med Clin. 2015;144(Suppl):3–15.
Easaw JC, Shea-Budgell MA, Wu CM, Czaykowski PM, Kassis J, Kuehl B, et al. Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis. Curr Oncol. 2015;22:133–43.
Hsu CC, Sandford BA. The Delphi technique: making sense of consensus. Practical assessment research & evaluation. 2007:12(10). http://pareonline.net/getvn.asp?v=12&n=10.
Dalkey N, Helmer O. An experimental application of the Delphi method to the use of experts. Manag Sci. 1963;9:458–67.
Baumann MH, Strange C, Heffner JE, Light R, Kirby TJ, Klein J, et al. Management of spontaneous pneumothorax*: an american college of chest physicians Delphi consensus statement. Chest. 2001;119:590–602.
Nunnally JC. Psychometric theory. New York: McGraw Hill; 1978. p. 701.
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383–94.
Mandala M, Falanga A, Roila F. Management of venous thromboembolism (VTE) in cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2011;22:vi85–92.
Key NS, Khorana AA, Mackman N, McCarty OJ, White GC, Francis CW, et al. Thrombosis in cancer: research priorities identified by a national cancer institute/national heart, lung, and blood institute strategic working group. Cancer Res. 2016;76:3671–5.
Cajfinger F, Debourdeau P, Lamblin A, Benatar V, Falvo N, Benhamou Y, et al. Low-molecular-weight heparins for cancer-associated thrombosis: adherence to clinical practice guidelines and patient perception in TROPIQUE, a 409-patient prospective observational study. Thromb Res. 2016;144:85–92.
Mahé I, Puget H, Buzzi JC, Lamuraglia M, Chidiac J, Strukov A, et al. Adherence to treatment guidelines for cancer-associated thrombosis: a French hospital-based cohort study. Support Care Cancer. 2016;24(8):3369–77.
Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost. 2013;11:56–70.
NCCN guidelines version 1.2016. Cancer associated venous thromboembolic disease. https://www.nccn.org/professionals/physician_gls/pdf/vte.pdf.
Ay C, Dunkler D, Marosi C, Chiriac A-L, Vormittag R, Simanek R, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116:5377–82.
Akl EA, Kahale LA, Barba M, Neumann I, Labedi N, Terrenato I, et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2014;7:CD006650.
Peris M, Jiménez D, Maestre A, Font C, Tafur AJ, Mazzolai L, et al. Outcome during and after anticoagulant therapy in cancer patients with incidentally found pulmonary embolism. Eur Respir J. 2016;48:1360–8.
Font C, Carmona-Bayonas A, Beato C, Reig Ò, Sáez A, Jiménez-Fonseca P, et al. Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EPIPHANY study. Eur Respir J. 2017;49:1600282.
Hulle T, Exter PL, Planquette B, Meyer G, Soler S, Monreal M, et al. Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients. J Thromb Haemost. 2016;14:105–13.
Gerber DE, Grossman SA, Streiff MB. Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol. 2006;24:1310–8.
Porta C, Imarisio I, Paglino C. Re: Damien Pouessel, Stéphane Culine. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol. 2008;53:1092–3.
Acknowledgements
Carmen González and Andreu Covas (GOT IT) for facilitating this Delphi project. Priscilla Chase Duran for editing and improving this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
This study consisted of a survey of expert opinions and no patient data were collected, so no specific independent ethical or research review or informed consent or approval was necessary.
Conflict of interest
Esteve Colomé works in Laboratories LEO Pharma, SA; he did not answer the questionnaire. The other authors declare that they have no conflict of interest.
Funding
The external consultant that managed the online platform for the realization of the study was funded by LEO Pharma Academy.
Rights and permissions
About this article
Cite this article
Jimenez-Fonseca, P., Carmona-Bayonas, A., Calderon, C. et al. FOTROCAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence. Clin Transl Oncol 19, 997–1009 (2017). https://doi.org/10.1007/s12094-017-1632-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-017-1632-3